NBP

$1.90+$0.03 (+1.60%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$216.3M

116M shares

52-week range

$1.46 – $5.19

12% from low

Exchange

NASDAQ

ADRC

Change$-2.65

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-3.29	$-3.29–$-3.29	—	1
2027	$0	—	$-4.96	$-4.96–$-4.96	—	1
2028	$107M	—	$-5.29	$-5.29–$-5.29	—	1
2029	$168M	+57.5%	$-5.80	$-5.80–$-5.80	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-07-30	$-0.01	$-0.22	-2660.4%
2025-12-18	$-0.06	$-0.08	-33.3%
2025-08-26	$-0.06	$-0.03	+58.3%
2025-05-15	$-0.06	$-0.02	+68.4%
2025-03-31	$-0.06	$-0.06	+0.0%
2024-11-14	$-0.16	$-0.25	-56.3%
2024-08-28	$-0.51	$-0.07	+86.3%

DCF fair valuemodel estimate

Intrinsic value

$0.11

Price

$1.90

Implied downside

-94%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
NBPNovaBridge Biosciences	$1.90	+1.60%	$219M	—
ALTAltimmune, Inc.	$2.88	-1.71%	$560M	—
ANNXAnnexon, Inc.	$5.26	-1.31%	$862M	—
AURAAura Biosciences, Inc.	$7.65	-1.29%	$791M	—
DMACDiaMedica Therapeutics Inc.	$6.75	-1.32%

NovaBridge Biosciences American Depositary Shares

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

www.novabridge.com

Employees: 30
IPO / List date: Jan 17, 2020

Held by traders on TradeandTell

No one on the platform currently holds NBP.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	272,412	$670.1K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded NBP yet.